<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052958</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.2 (26. Juni 2019)</org_study_id>
    <nct_id>NCT04052958</nct_id>
  </id_info>
  <brief_title>DM-IMT - Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1</brief_title>
  <acronym>DM-IMT</acronym>
  <official_title>DM-IMT - Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For some diseases, regular respiratory muscle training could delay the start of ventilation.
      For DM1, however, there are no clinically high-quality studies. Only a case description from
      the year 2006 showed a missing improvement of the symptoms after respiratory muscle training
      in one patient, accordingly there are no recommendations in this issue. Within the scope of
      this monocentric, three-arm, controlled intervention study, 45 patients with genetically
      confirmed type 1 myotonic dystrophy will be randomized in three groups of 15 patients each,
      age-, gender- and symptom-corrected by the MUSCULAR IMPAIRMENT RATING SCALE (MIRS). The DM1
      patients will receive regular respiratory muscle training for a period of 9 months. The aim
      of this study is to evaluate the safety and effectiveness of regular inspiratory
      strength-breathing muscle training on 15 patients, the safety and effectiveness of regular
      inspiratory endurance respiratory muscle training on 15 patients, and the comparison to the
      natural course in 15 patients without training. Subsequently, we will provide treatment
      recommendations for respiratory training in DM1.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">May 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of recurrent inspiratory muscle training</measure>
    <time_frame>nine months</time_frame>
    <description>Intervention-related (serious) adverse events will be assessed as described in protocoll DM-IMT Version 1.2 (26/June/2019). For example a deterioration of &gt; 15% of the FVC compared to the baseline measurements is defined as AE, as is the development of unusual myalgia of the respiratory muscles for more than 12 hours after the respiratory training. Detailed lists of patients experiencing adverse events or SAEs are reported. The severity of the adverse event is classified as mild, moderate or severe. Relationships of an AE to the training are categorized as unassociated, unlikely to be associated, possibly associated or associated. A separate list will be provided for patients who drop out of the study due to AEs. The frequency of adverse events leading to study termination is also summarized. Safety parameters also include lung function tests (PFT, including FVC, FEV1, MIP, MEP), physical examination, vital signs and clinical laboratory tests as required.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by MIP.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of Maximal inspiratory pressure (MIP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by MIP.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of Maximal inspiratory pressure (MIP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by MEP.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of Maximal exspiratory pressure (MEP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by MEP.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of Maximal exspiratory pressure (MEP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by FVC.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of Forced Vital capacity (FVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by FVC.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of Forced Vital capacity (FVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by FEV1.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of Forced Expiratory Volume in 1 second (FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by FEV1.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of Forced Expiratory Volume in 1 second (FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pCO2.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of pCO2 in capillary blood gas analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pCO2.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of pCO2 in capillary blood gas analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pO2.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of pO2 in capillary blood gas analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pO2.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of pO2 in capillary blood gas analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pH.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of pH in capillary blood gas analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pH.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of pH in capillary blood gas analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by 6-minute-walk-test.</measure>
    <time_frame>nine months</time_frame>
    <description>The efficacy of the respiratory training is determined by the results of 6-minute-walk-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by DM1-Activ.</measure>
    <time_frame>nine months</time_frame>
    <description>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of DM1-ACTIV, a Rasch-built DM activity and participation scale for clinical use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by FDSS.</measure>
    <time_frame>nine months</time_frame>
    <description>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the FDSS - FATIGUE AND DAYTIME SLEEPINESS SCALE, a Rasch-built combined fatigue and daytime sleepiness scale specifically designed for patients with DM1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by the questionnaire Respicheck.</measure>
    <time_frame>nine months</time_frame>
    <description>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the RESPICHECK, a questionnaire on clinical symptoms of respiratory insufficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by a physical examination.</measure>
    <time_frame>nine months</time_frame>
    <description>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the physical examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, using the 6-minute-walk-test.</measure>
    <time_frame>nine months</time_frame>
    <description>Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the 6-minute-walk-test.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Myotonic Dystrophy 1</condition>
  <arm_group>
    <arm_group_label>Group 1: Strength Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory muscle strength training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Endurance Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory muscle endurance training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no training of respiratory muscles</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IMT - inspiratory muscle training</intervention_name>
    <description>respiratory strength or indurance training with respiratory therapy device</description>
    <arm_group_label>Group 1: Strength Training</arm_group_label>
    <arm_group_label>Group 2: Endurance Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the patient is willing and able to provide a signed informed consent form

          -  the patient is â‰¥ 18 years old

          -  the diagnosis of type 1 myotonic dystrophy has been confirmed by molecular genetics

          -  the patient is able and willing to perform pulmonary function tests (PFT) and blood
             sampling for capillary blood gas analysis (pO2, pCO2) throughout the study, to keep a
             diary and to complete questionnaires

        Exclusion Criteria:

          -  the patient requires invasive ventilation (non-invasive ventilation is allowed).

          -  the patient uses non-invasive ventilation more than 16h/day.

          -  the patient participates in another clinical study that involves therapy.

          -  the patient cannot perform pulmonary function tests (PFT).

          -  the patient is diagnosed with central sleep apnea in polysomnography and not
             sufficiently treated with NIV ventilation.

          -  the patient is diagnosed with obstructive sleep apnea and not sufficiently treated
             with NIV ventilation.

          -  the patient cannot meet the requirements of the study, according to the investigator.

          -  the patient is unable to complete a 6-minute walking test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Wenninger, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Benedikt Schoser</investigator_full_name>
    <investigator_title>Neurologist, Senior Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04052958/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

